Table 1.
Clinical characteristics in prostate cancer (PCa) and benign prostate hyperplasia (BPH).
| Parameter | PCa n = 40 | BPH n = 40 | p value |
|---|---|---|---|
| Age (yrs) | 70.5 (64–73) | 67.4 (62.5–68.5) | 0.51a |
| BMI (kg/m2) | 26.4 (23.7–28.0) | 26.4 (25.2–29.1) | 0.20a |
| T-Chol (mg/dL) | 189.0 (170.0–220.0) | 190.5 (161.5–199.5) | 0.16a |
| HDL (mg/dL) | 39.5 (31.0–55.0) | 40.0 (29.5–55.0) | 0.78a |
| TG (mg/dL) | 152.6 ± 54.2 | 143.0 ± 43.6 | 0.38b |
| LDL (mg/dL) | 121.1 ± 28.7 | 123.0 ± 34.2 | 0.69b |
| Glucose (mg/dL) | 121.1 (104.0–126.5) | 122.0 (108.5–132.0) | 0.92a |
| Insulin (IU/dL) | 8.0 (5.7–11.0) | 9.8 (6.8–15.4) | 0.06a |
| HOMA-IR | 2.3 (1.7–3.7) | 2.8 (1.8–4.9) | 0.12a |
| Omentin (ng/mL) | 478.8 (398.2–584.7) | 408.3 (323.3–528.0) | 0.03b |
| Leptin (ng/mL) | 15.7 (8.2–26.8) | 11.2 (6.0–16.0) | 0.02b |
| VEGF (pg/mL) | 179.3 (116.0–266.0) | 123.3 (70.8–192.7) | <0.01b |
| HGF (pg/mL) | 359.5 (266.6–462.9) | 294.9 (192.1–353.7) | 0.04b |
| PSA (ng/mL) | 18.2 (7.7–30.8) | 9 (5.5–17) | <0.01a |
| Prostate volume in TRUS (cm3) | 31.1 (20.0–38.2) | 39.1 (24.9–47.5) | 0.02a |
Significant differences of examined parameters between groups have been bolded. Statistic tests: aMann–Whitney's U test, bStudent's t-test. PCa: prostate cancer; BPH: benign prostate hyperplasia; BMI: body mass index; T-Chol: total cholesterol; HDL: high-density lipoprotein; TG: triglycerides; LDL: low-density lipoprotein; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth factor.